Amphotericin B – Risk of Medication Error

Amphotericin B – Risk of Medication Error

In collaboration with the South African Health Products Regulatory Authority (SAHPRA) Bristol-Myers Squibb and Key Oncologies (Ply) Ltd would like to draw your attention to the risk of errors in prescribing, dispensing, preparing and administering different parenteral formulations of amphotericin B.

2019 Apr

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance